History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium
- PMID: 28293802
- PMCID: PMC5500209
- DOI: 10.1007/s10552-017-0867-1
History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium
Abstract
Purpose: Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.
Methods: Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.
Results: History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94.
Conclusions: Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.
Keywords: Beta blockers; Diabetes; Hypertension; Medications; Mortality; Ovarian cancer prognosis.
Conflict of interest statement
Similar articles
-
Antihypertensive medication use and ovarian cancer survival.Gynecol Oncol. 2021 Nov;163(2):342-347. doi: 10.1016/j.ygyno.2021.09.009. Epub 2021 Sep 21. Gynecol Oncol. 2021. PMID: 34556331 Free PMC article.
-
Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer.Int J Cancer. 2016 Jul 15;139(2):291-9. doi: 10.1002/ijc.30066. Epub 2016 Mar 25. Int J Cancer. 2016. PMID: 26934358 Free PMC article.
-
Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators.Int J Gynecol Cancer. 2024 Dec 2;34(12):1914-1923. doi: 10.1136/ijgc-2024-005663. Int J Gynecol Cancer. 2024. PMID: 39322609
-
The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.Arch Gynecol Obstet. 2021 Feb;303(2):285-311. doi: 10.1007/s00404-020-05865-z. Epub 2020 Nov 21. Arch Gynecol Obstet. 2021. PMID: 33222040 Review.
-
MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis.Medicine (Baltimore). 2018 Aug;97(32):e11505. doi: 10.1097/MD.0000000000011505. Medicine (Baltimore). 2018. PMID: 30095616 Free PMC article. Review.
Cited by
-
History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.Br J Cancer. 2017 Sep 26;117(7):1063-1069. doi: 10.1038/bjc.2017.267. Epub 2017 Aug 17. Br J Cancer. 2017. PMID: 28817835 Free PMC article.
-
A Novel Six-Gene Signature for Prognosis Prediction in Ovarian Cancer.Front Genet. 2020 Oct 15;11:1006. doi: 10.3389/fgene.2020.01006. eCollection 2020. Front Genet. 2020. PMID: 33193589 Free PMC article.
-
Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study.J Gynecol Oncol. 2018 Nov;29(6):e82. doi: 10.3802/jgo.2018.29.e82. J Gynecol Oncol. 2018. PMID: 30207092 Free PMC article.
-
Diabetes mellitus and hypertension increase the risk of colorectal cancer mortality; a robust Bayesian adjustment analysis.Gastroenterol Hepatol Bed Bench. 2017 Winter;10(Suppl1):S44-S47. Gastroenterol Hepatol Bed Bench. 2017. PMID: 29511471 Free PMC article.
-
Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.J Transl Med. 2018 May 1;16(1):114. doi: 10.1186/s12967-018-1489-4. J Transl Med. 2018. PMID: 29716620 Free PMC article.
References
-
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. - PubMed
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
-
- Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10. - PubMed
-
- Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S. Age as a prognostic factor in ovarian carcinoma. The gynecologic oncology group experience. Cancer. 1993;71:606–614. - PubMed
MeSH terms
Substances
Grants and funding
- P50 CA159981/CA/NCI NIH HHS/United States
- UL1 TR001412/TR/NCATS NIH HHS/United States
- R01 CA058598/CA/NCI NIH HHS/United States
- K22 CA138563/CA/NCI NIH HHS/United States
- R01 CA074850/CA/NCI NIH HHS/United States
- UL1 TR000124/TR/NCATS NIH HHS/United States
- K07 CA080668/CA/NCI NIH HHS/United States
- R01 CA188900/CA/NCI NIH HHS/United States
- R01 CA054419/CA/NCI NIH HHS/United States
- R01 CA076016/CA/NCI NIH HHS/United States
- K01 LM012100/LM/NLM NIH HHS/United States
- K07 CA095666/CA/NCI NIH HHS/United States
- R01 CA112523/CA/NCI NIH HHS/United States
- R01 CA126841/CA/NCI NIH HHS/United States
- R25 CA113951/CA/NCI NIH HHS/United States
- R01 CA087538/CA/NCI NIH HHS/United States
- P30 CA072720/CA/NCI NIH HHS/United States
- R01 CA095023/CA/NCI NIH HHS/United States
- T32 CA108456/CA/NCI NIH HHS/United States
- R01 CA080742/CA/NCI NIH HHS/United States
- P50 CA105009/CA/NCI NIH HHS/United States
- P30 CA138313/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical